【摘要】：目的:評價康萊特注射液聯(lián)合化療治療中晚期非小細(xì)胞肺癌(NSCLC)的療效和生活質(zhì)量改善情況及不良反應(yīng)。方法:論文一:根據(jù)Cochrane協(xié)作網(wǎng)系統(tǒng)評價方法,計算機(jī)檢索中國學(xué)術(shù)期刊全文數(shù)據(jù)庫(CNKI)、萬方數(shù)據(jù)庫,同時手工檢索雜志刊登的相關(guān)文獻(xiàn),檢索時間為2005年1月至2016年12月,全面收集符合標(biāo)準(zhǔn)的隨機(jī)對照試驗(RCT)。采取改良的Jadad量表評價文獻(xiàn)質(zhì)量,應(yīng)用Rev Man5.3軟件進(jìn)行Meta分析,分析指標(biāo)為計數(shù)資料,用比值比(OR)及其95%可信區(qū)間(95%CI)表示。論文二:收集2015年1月-2017年1月于遼寧中醫(yī)腫瘤科住院的中晚期NSCLC患者41例,按照治療方式不同分為2組,對照組予常規(guī)化療方案,治療組在此基礎(chǔ)上予康萊特注射液200ml/d靜點,21天為1療程,共進(jìn)行4個療程。本研究采用SPSS21.0軟件,進(jìn)行卡方檢驗,以P0.05為有意義。結(jié)果:論文一:1.共收集相關(guān)文獻(xiàn)343篇,其中納入15個改良的Jadad量表評分3分以上的隨機(jī)對照試驗,共計1230例中晚期NSCLC患者。較對照組,康萊特聯(lián)合化療治療NSCLC合并效應(yīng)量(OR=2.62,95%CI:1.79-3.83,Z=4.97,P0.00001)。改善生活質(zhì)量(OR=3.40,95%CI:2.51-4.60,Z=7.93,P0.00001)。減輕白細(xì)胞下降(OR=0.35,95%CI:0.24-0.50,Z=5.84,P0.00001)。降低胃腸道反應(yīng)(OR=0.52,95%CI:0.33-0.82,Z=2.80,P=0.005)。各項指標(biāo)較對照組差異均有統(tǒng)計學(xué)意義。論文二:2.回顧性分析得出康萊特試驗組總有效率為68.18%,對照組為36.84%,對比有統(tǒng)計學(xué)差異(P0.05);對照組在骨髓抑制方面的效果與試驗組近似,兩者比較無統(tǒng)計學(xué)差異(P0.05)。而對照組在產(chǎn)生消化道不良反應(yīng)方面較試驗組嚴(yán)重,且差異有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:1.康萊特注射液聯(lián)合化療在治療有效率方面較單純化療顯示出明顯優(yōu)勢。2.康萊特注射液在改善化療不良反應(yīng)方面效果肯定。3.康萊特注射液是一種綜合調(diào)整、療效確切且安全的治療中晚期NSCLC的中藥制劑。
[Abstract]:Objective: to evaluate the efficacy and quality of life (QOL) of Kanglaite injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: according to the systematic evaluation method of Cochrane collaborative network, we searched the (CNKI), Wanfang database of Chinese academic journal full-text database by computer, and searched the relevant literatures published in the journal by hand. The retrieval time was from January 2005 to December 2016. Comprehensive collection of standard randomized controlled trial (RCT). The improved Jadad scale was used to evaluate the literature quality. The Meta analysis was carried out by Rev Man5.3 software. The indexes were counted data and expressed by the ratio (OR) and its 95% confidence interval (95%CI). Thesis 2: 41 patients with advanced NSCLC hospitalized in Liaoning Cancer Department of traditional Chinese Medicine from January 2015 to January 2017 were divided into two groups according to the different treatment methods. The control group was given routine chemotherapy regimen, and the patients in the control group were divided into two groups according to the different treatment methods. On this basis, the treatment group was given Kanglaite injection 200ml/d intravenous point, 21 days as a course of treatment, a total of 4 courses. This research uses SPSS21.0 software, carries on the chi-square test, takes the P0.05 as the significance. Results: papers I: 1. A total of 343 literatures were collected, among which 15 randomized controlled trials with 3 or more scores were included in the modified Jadad scale. 1230 patients with advanced NSCLC were enrolled in this study. Compared with the control group, Kanglaite combined with chemotherapy in the treatment of NSCLC combined with response volume (OR=2.62,95%CI:1.79-3.83,Z=4.97,P0.00001). Improve the quality of life (OR=3.40,95%CI:2.51-4.60,Z=7.93,P0.00001). Reduce leukopenia (OR=0.35,95%CI:0.24-0.50,Z=5.84,P0.00001). Decrease gastrointestinal reaction (OR=0.52,95%CI:0.33-0.82,Z=2.80,P=0.005). Compared with the control group, all the indexes were significantly different from those in the control group. Thesis II: 2. Retrospective analysis showed that the total effective rate of Kanglaite test group was 68.18%, and that of control group was 36.84%, the difference was statistically significant (P0.05). The effect of myelosuppression in the control group was similar to that in the experimental group, but there was no significant difference between the two groups (P0.05). The side effects of digestive tract in the control group were more serious than those in the experimental group, and the difference was statistically significant (P0.05). Conclusions: 1. Kanglaite injection combined with chemotherapy showed obvious advantages over chemotherapy alone in the treatment of the effective rate. 2. The effect of Kanglaite injection in improving the side effects of chemotherapy is positive. 3. Kanglaite injection is a comprehensive adjustment, effective and safe Chinese medicine preparation for the treatment of advanced NSCLC.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李向東;董靈;;康萊特注射液聯(lián)合化療對晚期非小細(xì)胞肺癌生活質(zhì)量及骨髓抑制的影響[J];河北醫(yī)學(xué);2016年04期

2 付鵬;李翔;王超;毛柳英;曹俊嶺;;康萊特注射液在中晚期非小細(xì)胞肺癌治療中的臨床應(yīng)用研究[J];癌癥進(jìn)展;2016年03期

3 王樂;陳晨;張洪峰;王朝宗;李曉翠;;康萊特注射液上市后臨床安全性醫(yī)院集中監(jiān)測研究[J];環(huán)球中醫(yī)藥;2016年03期

4 王云;;胸腔鏡下不同術(shù)式肺葉切除術(shù)治療早期NSCLC的手術(shù)效果對比研究[J];臨床肺科雜志;2016年02期

5 陳偉偉;雷勵;蔡少華;陳麗;黨惠嬌;;康萊特注射液聯(lián)合化療治療晚期非小細(xì)胞肺癌的臨床療效[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2015年20期

6 王文萍;喻明;王麗;姜希仁;李曉斌;王華偉;曹瑩;劉凱;黃璐琦;;中藥新藥臨床試驗不良反應(yīng)及其相關(guān)影響因素的學(xué)術(shù)探討[J];中國中藥雜志;2015年02期

7 毛良平;孫锎;張萍;;康萊特輔助化療對晚期非小細(xì)胞肺癌患者生存期的影響[J];中國醫(yī)學(xué)前沿雜志(電子版);2014年07期

8 楊國旺;王皓;韓磊;初玉平;周愛軍;張俠;朱建華;富琦;張青;韓燕;王笑民;;中醫(yī)辨證論治方案聯(lián)合化療治療晚期非小細(xì)胞肺癌91例臨床觀察[J];中醫(yī)雜志;2014年03期

9 王曉青;王大中;;康萊特注射液聯(lián)合長春瑞濱+順鉑方案治療晚期非小細(xì)胞肺癌臨床觀察[J];遼寧中醫(yī)藥大學(xué)學(xué)報;2014年01期

10 梁素美;董佑紅;王靜;宋健;龔星;胡俊春;;康萊特聯(lián)合GP方案治療老年非小細(xì)胞肺癌25例[J];中醫(yī)學(xué)報;2014年01期

相關(guān)博士學(xué)位論文 前1條

1 姜恩順;扶正培元方對非小細(xì)胞肺癌化療患者生活質(zhì)量影響的臨床研究[D];中國中醫(yī)科學(xué)院;2013年

相關(guān)碩士學(xué)位論文 前1條

1 黃錦鵬;扶正抗癌方聯(lián)合吉非替尼治療晚期非小細(xì)胞肺癌生活質(zhì)量研究[D];廣州中醫(yī)藥大學(xué);2014年

，

本文編號：2433479